AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 12 min read$JAZZ

Pearce Samantha sold $1.6M of JAZZ

Pearce Samantha (EVP, Chief Commercial Officer) sold 6,907 shares of Jazz Pharmaceuticals plc (JAZZ) at $235.41 ($1.63M total) on 2026-05-28.

Original reporting
SEC EDGAR · Pearce Samantha
Published Jun 1, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$JAZZ
Neutral
medium confidence
Mentioned
$JAZZ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JAZZNeutralLow
01

Why it matters

The disclosure provides incremental sentiment information but does not change Jazz’s fundamentals or near-term catalyst calendar on its own.

02

Market read

Traders may briefly reassess sentiment around JAZZ, but the event is unlikely to drive a sustained repricing without corroborating news.

03

What to watch

No 10b5-1 plan is indicated, so traders may over-interpret; also, Form 4 timing reflects disclosure lag, not the exact market reaction day.

Relevance 6/10Novelty 6/10Timing: Filed June 1; sale executed May 28 (post-trade disclosure).

Background

SEC Form 4 reports insider transactions; this filing covers an open-market sale by Jazz’s EVP/Chief Commercial Officer.

Company-level read

Ticker impact

$JAZZNeutralMedium confidence
Context

Jazz Pharmaceuticals disclosed an open-market sale by its EVP/Chief Commercial Officer for $1.63M of shares.

Expected impact

Low near-term impact; any move is likely noise unless accompanied by other news.

Evidence & confidence

This is a Form 4 insider transaction with no 10b5-1 plan stated and no accompanying operational/clinical update.

Market effects

Sector

Minimal; single-company insider transaction without sector-wide read-through.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

The sale may be routine liquidity/portfolio rebalancing rather than a bearish view, especially given the modest size versus typical institutional float.

Key entities

  • issuer
    Jazz Pharmaceuticals plc

    Subject of the Form 4 insider sale by an executive officer.

  • insider
    Samantha Pearce

    EVP, Chief Commercial Officer who sold 6,907 shares at ~$235.41.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

JAZZ insider trading history →

Related articles

SEP 4
$JAZZHighAI 9/10

Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy showed a statistically significant overall survival benefit over trastuzumab in the Phase 3 HERIZON-GEA-01 trial. The study involved 914 patients across 30+ countries. The FDA approved Ziihera for first-line treatment of HER2-positive gastroesophageal adenocarcinoma, providing a commercial pathway. However, the magnitude of the survival benefit and safety concerns remain key factors for adoption.

insidermonkey.com3 min
SEP 2
$JAZZMedAI 8/10

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

Jazz Pharmaceuticals (JAZZ) shares fell 6.9% since its last earnings report. Q2 2026 adjusted EPS missed estimates at $5.71, but revenues rose 16% YoY to $1.21B, beating expectations. The company raised 2026 revenue guidance to $4.60-$4.75B. Xywav sales grew 13% YoY, while Xyrem sales declined 14% YoY. Oncology sales increased 32% YoY, driven by Zepzelca's 42% growth.

finance.yahoo.com2 min
SEP 2
$JAZZHighAI 8/10

Zanidatamab Plus Chemotherapy Extends OS in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals announced that zanidatamab plus chemotherapy showed improved overall survival in HER2+ advanced GEA patients compared to trastuzumab, per HERIZON-GEA-01 trial results. The HR for OS improved with longer follow-up. The FDA approved zanidatamab in August 2026 for first-line treatment, supported by earlier trial data. Jazz plans to present updated data at a medical meeting and submit findings to global health authorities.

cancernetwork.com2 min
AUG 31
$JAZZMedAI 8/10

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

Jazz Pharmaceuticals (JAZZ) shares rose 2.5% after positive Phase 3 trial results for Ziihera combined with chemotherapy in advanced gastroesophageal adenocarcinoma. The trial showed a statistically significant overall survival benefit, reinforcing the drug's potential. The stock closed at $250.79, up 2.6% from the previous close. JAZZ is up 44.8% year-to-date and near its 52-week high of $261.62.

financialcontent.com2 min
AUG 31
$JAZZHighAI 8/10

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals (JAZZ) reported that Ziihera, combined with chemotherapy, showed statistically significant overall survival benefits in a Phase 3 trial for HER2+ advanced gastroesophageal adenocarcinoma (GEA). The results support Ziihera as a new standard of care, following its recent FDA approval. The company plans to present the data at a major medical meeting in Q4 2026.

prnewswire.com2 min